NCT00590265Completed
Light-Therapy in the Treatment of the Acute Phase of the Bipolar Type II Depression
Light-Therapy in the Treatment of the Acute Phase of the Bipolar Type II Depression: Double-Blind, Placebo-Controlled Study to Establish Efficacy and Safety
Source: ClinicalTrials.gov · Last updated 27 Aug 2026
Brief summary (registry, in English)
The purpose of this study is to evaluate the efficacy and safety of light therapy for the treatment of bipolar type II patients relapsing into a depressive phase during autumn or winter.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 31 (actual)
- First submitted
- 26 Dec 2007
- Start date
- Jan 2008
- Primary completion date
- 27 Oct 2025
- Lead sponsor
- Douglas Mental Health University Institute
- Diseases
- Bipolar disorder
- NCT number
- NCT00590265
What you commit to
- Study type: Interventional
- Participants enrolled: 31
- From Jan 2008 to the primary completion date, 27 Oct 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- History of manic or hypomanic switch when exposed to bright light or during prolonged exposure to the sun during previous depressive phases
- Alcohol or drug abuse
- Known skin sensitivity to sunlight, especially in patients receiving photosensitizing drugs such as lithium or phenothiazines
Other illness
- Other psychiatric condition, organic brain disorder, unstable and/or untreated medical condition such as hypothyroidism, diabetes, cardiac condition, hypertension
- History of light-induced migraine or epilepsy
- Glaucoma, retinal diseases of the eye
- Past history of light therapy
Other
- Deficit in vitamin B12 or folate
- Sub-syndromic hypomania symptoms as per a Young Mania Rating Scale (YMRS) score ≥ 4
- Pregnancy or absence of a contraceptive treatment
- Marked suicidal ideation
- Retinal blindness or severe cataract
Who the study is looking for
- Bipolar type II disorder, depressive phase meeting DSM-IV criteria as per the SCID interview
- Hamilton Depression Rating Scale 21 items (HAMD-21) ≥ 17 and a Montgomery Asberg rating Scale (MADRS) ≥ 15 for at least 2 weeks and the episode has begun during the month of september or a later month
- Able to give their consent and willingness to participate to the study
Age in the registry: 18 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Douglas Mental Health University Institute Coordinator of this site? Confirm its status | Montreal | Canada | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.